Skip to main content
OpenTrials
Completed

NCT Number: NCT00890942

Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section

The purpose of this study is to determine whether intramuscular naloxone 0.4mg. is effective in prophylaxis of intrathecal morphine induced pruritus after cesarean section.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Anesthesiology department, Siriraj Hospital, Mahidol University

Bangkok, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patient schedule for cesarean section ASA class 1

Exclusion criteria

  • have contraindication for spinal block
  • complicated pregnancy
  • have history of drug abuse during pregnancy
  • obesity BMI>35kg./m2

Treatment and study plan

naloxone

Drug

naloxone 0.4mg.(1 ml) intramuscular

Other names: narcan

normal saline

Drug

normal saline 1 ml IM

Primary outcomes

  1. efficacy of intrathecal naloxone 0.4mg. in prophylaxis of intrathecal morphine induced pruritus after cesarean section

    Time frame: 24 hour

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Registry information

Official study title

Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Apr 30, 2009
Registry last updated
Jul 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.